Previous 10 | Next 10 |
2023-08-10 11:40:10 ET MorphoSys AG (MOR) Q2 2023 Earnings Conference Call August 10, 2023 8:00 AM ET Company Participants Julia Neugebauer – Head of Investor Relations Jean-Paul Kress – Chief Executive Officer Tim Demuth – Chief Research and...
2023-08-09 16:52:31 ET MorphoSys press release ( NASDAQ: MOR ): Q2 GAAP EPS of -€$2.16. Revenue of €53.2M (-10.4% Y/Y). For further details see: MorphoSys GAAP EPS of -€$2.16, revenue of €$53.2M
– Monjuvi ® U.S. net product sales of US$ 23.6 million (€ 21.7 million) for the second quarter of 2023 – Enrollment of Phase 3 MANIFEST-2 study of pelabresib in first-line myelofibrosis is complete, with topline data expected by the end of 2023 ȁ...
2023-06-16 19:30:59 ET JP Morgan has upgraded MorphoSys ( NASDAQ: MOR ) to overweight, citing upcoming data from a Phase 3 clinical study for its drug pelabresib in the treatment of myelofibrosis, a type of bone marrow cancer. The investment bank said that positive results would...
2023-06-16 08:33:21 ET Virgin Galactic ( SPCE ) +42% stock movers today: Virgin Galactic, Coherent and more. VCI Global ( VCIG ) +35% Marks Debut into Artificial Intelligence (“AI”) and Big Data Industries Through Partnership with Fusionex. ...
2023-06-14 08:32:02 ET Advanced Health Intelligence ( AHI ) -25% . Eastside Distilling ( EAST ) -24% on plans for exchanging debt for equity with lenders . Coeptis Therapeutics Holdings ( COEP ) -21% . IperionX Limited ( IPX ) -16% . IO ...
2023-05-22 11:17:03 ET Summary Sales beat: Despite Monjuvi's setbacks, MorphoSys exceeds Q1 2023 sales expectations with €62.3m and robust 11% YoY US growth. Pelabresib Potential: Accelerated MANIFEST-2 Pelabresib data readout could be a key catalyst, promising MF candidate...
2023-05-19 11:27:29 ET BofA Securities has initiated Xencor ( NASDAQ: XNCR ) with a buy highlighting its pipeline of protein therapeutics for cancer and inflammatory diseases. The firm has a $42 price target (~61% upside based on Thursday's close) in Friday morning trading. ...
2023-05-06 03:08:07 ET MorphoSys AG (MOR) Q1 2023 Earnings Conference Call May 04, 2023, 8:00 AM ET Company Participants Julia Neugebauer - Vice President, Head of Investor Relations Jean-Paul Kress - Chief Executive Officer Tim Demuth - Chief Research and Develo...
2023-05-03 17:37:36 ET MorphoSys press release ( NASDAQ: MOR ): Q1 GAAP EPS of -€1.30. Revenue of €62.3M (+50.1% Y/Y). Monjuvi ® U.S. net product sales of US$ 20.8 million (€ 19.4 million) for the first quarter of 2023. €79...
News, Short Squeeze, Breakout and More Instantly...
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that it has formally notified the Nasdaq Stock Market of its intention to voluntarily delist its American Depositary Shares (“ADSs”) from the Nasdaq Global Market and to deregister the ADSs under Section 12(b) of the Securities Ex...
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following the successful closing of the acquisition of MorphoSys by Novartis in May 2024. Novartis BidCo Germany AG (together with Novartis BidCo AG ...
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 20, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG. Novartis BidCo Germany ...